BIOPTRON Hyperlight Therapy is an extraordinary technology that offers an effective and economical treatment for complex and non-healing wounds, on any part of the body, including those caused by diabetes, vascular disease, high blood pressure and other health problems.
Hyperlight Therapy considerably enhances the natural regeneration processes of the tissues, for faster wound healing with minimal scarring.
BIOPTRON Hyperlight Therapy reduces the risk of infections, decreases the number of costly wound dressings, shortens hospitalization stay and promotes overall wellbeing.
BIOPTRON is clinically tested and certified for the medical treatment of:
• Wounds following trauma or surgery
• BurnsSkin grafts
• Venous leg ulcers (stasis ulcers)
• Decubitus (pressure ulcers)
• Diabetic foot ulcers
Bioptron Hyperlight Therapy accelerates the reparative cellular processes, decreasing the risk of infection and diminishing pain during the whole healing process. The regenerated tissues are more elastic, healthy and scar-free.
HOW BIOPTRON HYPERLIGHT TREATS WOUNDS?
BIOPTRON Hyperlight increases the mobility and migration of fibroblasts:
In every wound, the regeneration of tissues is a pivotal process. BIOPTRON Hyperlight increases the mobility of newly-formed fibroblasts, a critical process to wound healing. BIOPTRON Hyperlight promotes the expression of the binding factors that support this migration, contributing actively to the faster and healthier regeneration of the damaged skin. (Publication ongoing).
BIOPTRON Hyperlight increases collagen production:
BIOPTRON Hyperlight increases the production of endogen collagen, giving to the connective tissues the structure and stability necessary for elasticity and skin strength.
BIOPTRON Hyperlight therapy fosters the recovery of tissues to a healthy and functional state (De Melo et al., 2016).
BIOPTRON Hyperlight improves microcirculation:
BIOPTRON Hyperlight increases the blood flow in irradiated capillaries, boosting the oxygen and nutrients supply, as well as the uptake of nocive substances produced by damaged cells. BIOPTRON Hyperlight therapy provides to the new-formed cells all they need to favour healthy tissue regeneration (Samoilova et al., 2008).
BIOPTRON Hyperlight promotes angiogenesis:
Chronic wounds are very often characterized by poor and deficient blood supply, which could slow down and delay the recovery. BIOPTRON Hyperlight promotes angiogenesis by developing new capillaries. The increased number and length of capillaries contribute to healthy tissue regeneration and shorter recovery time (Gasparyan et al., 2005).
BIOPTRON Hyperlight decreases the risk of infections and reinforces the immune system:
Infections are a major risk factor in chronic open wounds that negatively affect wound management. BIOPTRON Hyperlight contains blue light, which is very well known for its intrinsic antimicrobial effect, without the addition of exogenous photosensitizers. The regular use of BIOPTRON Hyperlight prevents the development of bacterial infection (Opel et al, 2015). In parallel, Bioptron Hyperlight Therapy increases IL-6, which increases the production of IgM antibodies by B lymphocytes, providing defence against blood-borne pathogens (Fenyo et al., 1992). The secretion of IFN-γ is as well promoted, reinforcing the microbicidal and antiviral action of natural killer cells (Zhevago, 2006).
BIOPTRON Hyperlight diminishes inflammation:
BIOPTRON Hyperlight decreases the production of pro-inflammatory cytokines, such as TNF-α, and increases anti-inflammatory cytokines, such as TGF –β and IL-10, in the irradiated region, reducing locally the inflammation of affected epithelium (Falus et al 2011, Zhevago 2006).
BIOPTRON Hyperlight relieves pain:
Constant and intolerable pain is disabling and devastating in patients with chronic wounds. Pain impairs wound healing and slows down patient recovery. Bioptron Hyperlight Therapy reduces pain by stimulating the production of nitric oxide, which decreases the over-stimulation of somatic peripheral nerves and increases vasodilatation, diminishing in parallel the ischemic pain (Gaspariyan et al., 2005; Samoilova et al., 2008).